(Q53045254)

10 May 2018

title

SUV of [68Ga]DOTATOC-PET/CT Predicts Response Probability of PRRT in Neuroendocrine Tumors. (English)

1 reference

10 May 2018

Antonia Dimitrakopoulou-Strauss

author

5

1 reference

10 May 2018

Ali Afshar-Oromieh

object named as

A Afshar-Oromieh

6

0 references

author name string

C Kratochwil

1

1 reference

10 May 2018

M Stefanova

2

1 reference

10 May 2018

E Mavriopoulou

3

1 reference

10 May 2018

T Holland-Letz

4

1 reference

10 May 2018

W Mier

7

1 reference

10 May 2018

U Haberkorn

8

1 reference

10 May 2018

F L Giesel

9

1 reference

10 May 2018

publication date

1 June 2015

1 reference

10 May 2018

Molecular Imaging and Biology

published in

1 reference

10 May 2018

volume

17

1 reference

10 May 2018

issue

3

1 reference

10 May 2018

page(s)

313-318

1 reference

10 May 2018

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11307-014-0795-3

Gastroenteropancreatic neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-014-0795-3

First‐line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-014-0795-3

Everolimus for advanced pancreatic neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-014-0795-3

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-014-0795-3

Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-014-0795-3

Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-014-0795-3

68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-014-0795-3

Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET/CT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-014-0795-3

Comparison of neuroendocrine tumor detection and characterization using DOTATOC-PET in correlation with contrast enhanced CT and delayed contrast enhanced MRI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-014-0795-3

Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-014-0795-3

Standardized uptake values of (68)Ga-DOTANOC PET: a promising prognostic tool in neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-014-0795-3

Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-014-0795-3

Peptide receptor radionuclide therapy with Y-DOTATOC and (177)Lu-DOTATOC in advanced neuroendocrine tumors: results from a Danish cohort treated in Switzerland

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-014-0795-3

Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-014-0795-3

Yttrium-90-labelled somatostatin-analogue for cancer treatment

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25319765

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S11307-014-0795-3

1 reference

10 May 2018

1 reference

10 May 2018